For the Year Ended
December 31, 2023

For the Period from July 11, 2022 through December 31, 2022

Net loss available to Class A ordinary shareholders

$

(35,468

)

$

(14,400

)

(Increase)/Decrease in ProKidney Corp. accumulated deficit for impact of
   subsidiary equity-based compensation

7,005

6,150

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for exchange
   of Common Units in ProKidney LP for Class A ordinary shares

(9,500

)

–

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for vesting of
   Restricted Common Units in ProKidney LP

(4,795

)

(321

)

Change from net loss available to Class A ordinary shareholders and change
   in ownership interest in ProKidney LP

$

(42,758

)

$

(8,571

)